These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 27106834)
21. Development of Fluorinated Analogues of Perhexiline with Improved Pharmacokinetic Properties and Retained Efficacy. Tseng CC; Noordali H; Sani M; Madhani M; Grant DM; Frenneaux MP; Zanda M; Greig IR J Med Chem; 2017 Apr; 60(7):2780-2789. PubMed ID: 28277663 [TBL] [Abstract][Full Text] [Related]
22. Is perhexiline essential for the optimal management of angina pectoris? Horowitz JD; Button IK; Wing L Aust N Z J Med; 1995 Apr; 25(2):111-3. PubMed ID: 7605290 [No Abstract] [Full Text] [Related]
23. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure. Rupp H; Zarain-Herzberg A; Maisch B Herz; 2002 Nov; 27(7):621-36. PubMed ID: 12439634 [TBL] [Abstract][Full Text] [Related]
24. Direct evidence that perhexiline modifies myocardial substrate utilization from fatty acids to lactate. Jeffrey FM; Alvarez L; Diczku V; Sherry AD; Malloy CR J Cardiovasc Pharmacol; 1995 Mar; 25(3):469-72. PubMed ID: 7769814 [TBL] [Abstract][Full Text] [Related]
30. Effects of perhexiline-induced fuel switch on the cardiac proteome and metabolome. Yin X; Dwyer J; Langley SR; Mayr U; Xing Q; Drozdov I; Nabeebaccus A; Shah AM; Madhu B; Griffiths J; Edwards LM; Mayr M J Mol Cell Cardiol; 2013 Feb; 55():27-30. PubMed ID: 23277191 [TBL] [Abstract][Full Text] [Related]
31. Metabolic abnormalities of the heart in type II diabetes. Amaral N; Okonko DO Diab Vasc Dis Res; 2015 Jul; 12(4):239-48. PubMed ID: 25941161 [TBL] [Abstract][Full Text] [Related]
32. [Perhexiline maleate in a multicentric study in Brazil - a new model of a clinical protocol and mechanism of action of the drug]. Bozza A; de Britto AH; Malagrino A; Nogueira A; Besen D; Santos DV; Di Piero EF; Ferreira FM; Gomes FJ; de Brito FS; Dohmann H; Arroyo JB; Batlouni M; Wagner M; Studart PC; Duprat R; Federico W Arq Bras Cardiol; 1979 Apr; 32(4):263-8. PubMed ID: 389211 [No Abstract] [Full Text] [Related]
35. [Clinical efficacy of perhexiline maleate in stable angina pectoris (author's transl)]. Linkesch W; Glogar D; Niederberger M Wien Klin Wochenschr; 1978 Sep; 90(16):598-603. PubMed ID: 695649 [TBL] [Abstract][Full Text] [Related]
36. [Cardiovascular effects of N-ethyl perhexiline maleate in animals]. Meng HP; Zhang BH Yao Xue Xue Bao; 1985 Jun; 20(6):401-4. PubMed ID: 4096229 [No Abstract] [Full Text] [Related]
37. The treatment of angina pectoris. A trial of perhexiline maleate in patients with angiographically normal coronary arteries. Day LJ; Sowton E Practitioner; 1978 Jun; 220(1320):965-8. PubMed ID: 356021 [No Abstract] [Full Text] [Related]
38. Investigations of long-term treatment with perhexiline maleate using therapeutic monitoring and electromyography. Pilcher J; Cooper JD; Turnell DC; Matenga J; Paul R; Lockhart JD Ther Drug Monit; 1985; 7(1):54-60. PubMed ID: 3992623 [TBL] [Abstract][Full Text] [Related]
39. Papilledema without peripheral neuropathy in a patient taking perhexiline maleate. Mandelcorn M; Murphy J; Colman J Can J Ophthalmol; 1982 Aug; 17(4):173-5. PubMed ID: 7127202 [TBL] [Abstract][Full Text] [Related]
40. Changes in the cardiac metabolome caused by perhexiline treatment in a mouse model of hypertrophic cardiomyopathy. Gehmlich K; Dodd MS; Allwood JW; Kelly M; Bellahcene M; Lad HV; Stockenhuber A; Hooper C; Ashrafian H; Redwood CS; Carrier L; Dunn WB Mol Biosyst; 2015 Feb; 11(2):564-73. PubMed ID: 25437646 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]